{"transactions":[{"id":4631089,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-10-05T22:05:55.000Z","date":"2026-10-01","kind":"exercise","planned":true,"acquired":false,"shares":17750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Reflects an award of stock options to purchase Common Shares that is fully vested."}],"balance_after":151416,"derivative":{"exercise_price":4.46,"expiration_date":"2032-07-19","underlying":"Common Stock","underlying_shares":17750},"source":{"system":"sec-edgar","filing":"0001807359-26-000018","document":"wk-form4_1791237952.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000180735926000018/wk-form4_1791237952.xml","form_type":"4"}},{"id":4631088,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-10-05T22:05:55.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":900,"price":36.57,"value":32913.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.48 to $36.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026."}],"balance_after":14954,"source":{"system":"sec-edgar","filing":"0001807359-26-000018","document":"wk-form4_1791237952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000180735926000018/wk-form4_1791237952.xml","form_type":"4"}},{"id":4631087,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-10-05T22:05:55.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":16850,"price":36.08,"value":607948.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.46 to $36.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026."}],"balance_after":15854,"source":{"system":"sec-edgar","filing":"0001807359-26-000018","document":"wk-form4_1791237952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000180735926000018/wk-form4_1791237952.xml","form_type":"4"}},{"id":4631086,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-10-05T22:05:55.000Z","date":"2026-10-01","kind":"exercise","planned":true,"acquired":true,"shares":17750,"price":4.46,"value":79165.0,"ownership":{"direct":true},"balance_after":32704,"source":{"system":"sec-edgar","filing":"0001807359-26-000018","document":"wk-form4_1791237952.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000180735926000018/wk-form4_1791237952.xml","form_type":"4"}},{"id":4628452,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2026-10-03T01:00:55.000Z","date":"2026-09-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":76171,"price":36.57,"value":2785573.47,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."}],"balance_after":16583774,"source":{"system":"sec-edgar","filing":"0001140361-26-038475","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750094/000114036126038475/form4.xml","form_type":"4"}},{"id":4628453,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32849,"kind":"person","name":"Torti Frank","position":1,"cik":"0001647805","reported_name":"Torti Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Vant Chair"}}],"security":"Common Shares","published_at":"2026-10-03T01:00:11.000Z","date":"2026-09-30","kind":"tax_withholding","planned":false,"acquired":true,"shares":40309,"price":36.57,"value":1474100.13,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."}],"balance_after":13495893,"source":{"system":"sec-edgar","filing":"0001140361-26-038474","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1647805/000114036126038474/form4.xml","form_type":"4"}},{"id":4629063,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":20848,"kind":"person","name":"Sukhatme Mayukh","position":1,"cik":"0001750050","reported_name":"Sukhatme Mayukh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CIO"}}],"security":"Common Shares","published_at":"2026-10-02T21:38:42.000Z","date":"2026-09-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":46879,"price":36.57,"value":1714365.03,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."}],"balance_after":18583860,"source":{"system":"sec-edgar","filing":"0001635088-26-000109","document":"wk-form4_1790977119.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750050/000163508826000109/wk-form4_1790977119.xml","form_type":"4"}},{"id":4629067,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & Immunovant CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-10-02T21:37:41.000Z","date":"2026-09-30","kind":"exercise","planned":true,"acquired":false,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Reflects an award of stock options to purchase Common Shares that is fully vested."}],"balance_after":3644834,"derivative":{"exercise_price":3.85,"expiration_date":"2032-04-19","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001635088-26-000108","document":"wk-form4_1790977058.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000163508826000108/wk-form4_1790977058.xml","form_type":"4"}},{"id":4629066,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2026-10-02T21:37:41.000Z","date":"2026-09-30","kind":"sale","planned":true,"acquired":false,"shares":200000,"price":36.62,"value":7324000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.49 to $36.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025."}],"balance_after":1599154,"source":{"system":"sec-edgar","filing":"0001635088-26-000108","document":"wk-form4_1790977058.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000163508826000108/wk-form4_1790977058.xml","form_type":"4"}},{"id":4629065,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2026-10-02T21:37:41.000Z","date":"2026-09-30","kind":"exercise","planned":true,"acquired":true,"shares":200000,"price":3.85,"value":770000.0,"ownership":{"direct":true},"balance_after":1799154,"source":{"system":"sec-edgar","filing":"0001635088-26-000108","document":"wk-form4_1790977058.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000163508826000108/wk-form4_1790977058.xml","form_type":"4"}},{"id":4625094,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":36061,"kind":"person","name":"Humes Jennifer","position":1,"cik":"0002058012","reported_name":"Humes Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Shares","published_at":"2026-09-23T01:00:18.000Z","date":"2026-09-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":3880,"price":39.77,"value":154307.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes Common Shares purchased under the Company's Employee Stock Purchase Plan."}],"balance_after":106419,"source":{"system":"sec-edgar","filing":"0001140361-26-037363","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2058012/000114036126037363/form4.xml","form_type":"4"}},{"id":4624949,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":20422,"kind":"person","name":"Pulik Richard","position":1,"cik":"0001885841","reported_name":"Pulik Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Shares","published_at":"2026-09-22T22:26:44.000Z","date":"2026-09-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":2129,"price":39.77,"value":84670.33,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."}],"balance_after":269681,"source":{"system":"sec-edgar","filing":"0001635088-26-000104","document":"wk-form4_1790116002.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885841/000163508826000104/wk-form4_1790116002.xml","form_type":"4"}},{"id":4622978,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":22745,"kind":"person","name":"Gold Daniel Allen","position":1,"cik":"0001832142","reported_name":"Gold Daniel Allen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-18T23:12:51.000Z","date":"2026-09-16","kind":"grant","planned":false,"acquired":true,"shares":10531,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date."}],"balance_after":10531,"derivative":{"exercise_price":39.57,"expiration_date":"2036-09-15","underlying":"Common Shares","underlying_shares":10531},"source":{"system":"sec-edgar","filing":"0001635088-26-000102","document":"wk-form4_1789773168.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1832142/000163508826000102/wk-form4_1789773168.xml","form_type":"4"}},{"id":4622977,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":22745,"kind":"person","name":"Gold Daniel Allen","position":1,"cik":"0001832142","reported_name":"Gold Daniel Allen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-09-18T23:12:51.000Z","date":"2026-09-16","kind":"grant","planned":false,"acquired":true,"shares":5054,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an annual award of restricted stock units with respect to Common Shares (\"RSUs\") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an annual award of restricted stock units with respect to Common Shares (\"RSUs\") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date."}],"balance_after":8965815,"source":{"system":"sec-edgar","filing":"0001635088-26-000102","document":"wk-form4_1789773168.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1832142/000163508826000102/wk-form4_1789773168.xml","form_type":"4"}},{"id":4622980,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29297,"kind":"person","name":"Oren Ilan","position":1,"cik":"0001643073","reported_name":"Oren Ilan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-18T23:06:43.000Z","date":"2026-09-16","kind":"grant","planned":false,"acquired":true,"shares":10531,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date."}],"balance_after":10531,"derivative":{"exercise_price":39.57,"expiration_date":"2036-09-15","underlying":"Common Shares","underlying_shares":10531},"source":{"system":"sec-edgar","filing":"0001635088-26-000099","document":"wk-form4_1789772800.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643073/000163508826000099/wk-form4_1789772800.xml","form_type":"4"}},{"id":4622979,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29297,"kind":"person","name":"Oren Ilan","position":1,"cik":"0001643073","reported_name":"Oren Ilan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-09-18T23:06:43.000Z","date":"2026-09-16","kind":"grant","planned":false,"acquired":true,"shares":5054,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an annual award of restricted stock units with respect to Common Shares (\"RSUs\") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an annual award of restricted stock units with respect to Common Shares (\"RSUs\") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date."}],"balance_after":123680,"source":{"system":"sec-edgar","filing":"0001635088-26-000099","document":"wk-form4_1789772800.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643073/000163508826000099/wk-form4_1789772800.xml","form_type":"4"}},{"id":4622982,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-18T23:01:43.000Z","date":"2026-09-16","kind":"grant","planned":false,"acquired":true,"shares":10531,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date."}],"balance_after":10531,"derivative":{"exercise_price":39.57,"expiration_date":"2036-09-15","underlying":"Common Shares","underlying_shares":10531},"source":{"system":"sec-edgar","filing":"0001209181-26-000007","document":"wk-form4_1789772501.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000120918126000007/wk-form4_1789772501.xml","form_type":"4"}},{"id":4622981,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-09-18T23:01:43.000Z","date":"2026-09-16","kind":"grant","planned":false,"acquired":true,"shares":5054,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an annual award of restricted stock units with respect to Common Shares (\"RSUs\") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an annual award of restricted stock units with respect to Common Shares (\"RSUs\") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date."}],"balance_after":111959,"source":{"system":"sec-edgar","filing":"0001209181-26-000007","document":"wk-form4_1789772501.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000120918126000007/wk-form4_1789772501.xml","form_type":"4"}},{"id":4622995,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32848,"kind":"person","name":"Fitzgerald Meghan","position":1,"cik":"0001349297","reported_name":"Fitzgerald Meghan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-18T22:57:24.000Z","date":"2026-09-16","kind":"grant","planned":false,"acquired":true,"shares":10531,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date."}],"balance_after":10531,"derivative":{"exercise_price":39.57,"expiration_date":"2036-09-15","underlying":"Common Shares","underlying_shares":10531},"source":{"system":"sec-edgar","filing":"0001349297-26-000010","document":"wk-form4_1789772242.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000134929726000010/wk-form4_1789772242.xml","form_type":"4"}},{"id":4622994,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32848,"kind":"person","name":"Fitzgerald Meghan","position":1,"cik":"0001349297","reported_name":"Fitzgerald Meghan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-09-18T22:57:24.000Z","date":"2026-09-16","kind":"grant","planned":false,"acquired":true,"shares":5054,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an annual award of restricted stock units with respect to Common Shares (\"RSUs\") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an annual award of restricted stock units with respect to Common Shares (\"RSUs\") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date."}],"balance_after":41162,"source":{"system":"sec-edgar","filing":"0001349297-26-000010","document":"wk-form4_1789772242.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000134929726000010/wk-form4_1789772242.xml","form_type":"4"}},{"id":4624135,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-18T22:56:09.000Z","date":"2026-09-16","kind":"grant","planned":false,"acquired":true,"shares":10531,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date."}],"balance_after":10531,"derivative":{"exercise_price":39.57,"expiration_date":"2036-09-15","underlying":"Common Shares","underlying_shares":10531},"source":{"system":"sec-edgar","filing":"0001807359-26-000016","document":"wk-form4_1789772167.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000180735926000016/wk-form4_1789772167.xml","form_type":"4"}},{"id":4624134,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-09-18T22:56:09.000Z","date":"2026-09-16","kind":"grant","planned":false,"acquired":true,"shares":5054,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an annual award of restricted stock units with respect to Common Shares (\"RSUs\") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an annual award of restricted stock units with respect to Common Shares (\"RSUs\") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date."}],"balance_after":14954,"source":{"system":"sec-edgar","filing":"0001807359-26-000016","document":"wk-form4_1789772167.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000180735926000016/wk-form4_1789772167.xml","form_type":"4"}},{"id":4622116,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-09-17T22:43:13.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":600,"price":40.38,"value":24228.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.25 to $40.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026."}],"balance_after":9900,"source":{"system":"sec-edgar","filing":"0001807359-26-000014","document":"wk-form4_1789684991.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000180735926000014/wk-form4_1789684991.xml","form_type":"4"}},{"id":4622115,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-09-17T22:43:13.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":4338,"price":39.65,"value":172001.7,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.25 to $40.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026."}],"balance_after":10500,"source":{"system":"sec-edgar","filing":"0001807359-26-000014","document":"wk-form4_1789684991.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000180735926000014/wk-form4_1789684991.xml","form_type":"4"}},{"id":4622114,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32848,"kind":"person","name":"Fitzgerald Meghan","position":1,"cik":"0001349297","reported_name":"Fitzgerald Meghan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-09-17T22:42:16.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":400,"price":40.45,"value":16180.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.28 to $40.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026."}],"balance_after":36108,"source":{"system":"sec-edgar","filing":"0001349297-26-000008","document":"wk-form4_1789684933.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000134929726000008/wk-form4_1789684933.xml","form_type":"4"}},{"id":4622113,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32848,"kind":"person","name":"Fitzgerald Meghan","position":1,"cik":"0001349297","reported_name":"Fitzgerald Meghan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-09-17T22:42:16.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":4712,"price":39.68,"value":186972.16,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.26 to $40.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026."}],"balance_after":36508,"source":{"system":"sec-edgar","filing":"0001349297-26-000008","document":"wk-form4_1789684933.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000134929726000008/wk-form4_1789684933.xml","form_type":"4"}},{"id":4617585,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":22745,"kind":"person","name":"Gold Daniel Allen","position":1,"cik":"0001832142","reported_name":"Gold Daniel Allen","relationship":{"director":true}}],"security":"Common Shares","published_at":"2026-09-15T01:00:17.000Z","date":"2026-09-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":5133,"price":40.94,"value":210145.02,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares."}],"balance_after":8960761,"source":{"system":"sec-edgar","filing":"0001140361-26-036535","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1832142/000114036126036535/form4.xml","form_type":"4"}},{"id":4617462,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29297,"kind":"person","name":"Oren Ilan","position":1,"cik":"0001643073","reported_name":"Oren Ilan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-09-14T22:42:32.000Z","date":"2026-09-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":2378,"price":40.94,"value":97355.32,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares."}],"balance_after":118626,"source":{"system":"sec-edgar","filing":"0001635088-26-000092","document":"wk-form4_1789425749.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643073/000163508826000092/wk-form4_1789425749.xml","form_type":"4"}},{"id":4617449,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-09-14T22:34:01.000Z","date":"2026-09-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":2179,"price":40.94,"value":89208.26,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares."}],"balance_after":14838,"source":{"system":"sec-edgar","filing":"0001807359-26-000012","document":"wk-form4_1789425238.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000180735926000012/wk-form4_1789425238.xml","form_type":"4"}},{"id":4617447,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32848,"kind":"person","name":"Fitzgerald Meghan","position":1,"cik":"0001349297","reported_name":"Fitzgerald Meghan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-09-14T22:29:07.000Z","date":"2026-09-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":1743,"price":40.94,"value":71358.42,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares."}],"balance_after":41220,"source":{"system":"sec-edgar","filing":"0001349297-26-000006","document":"wk-form4_1789424944.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000134929726000006/wk-form4_1789424944.xml","form_type":"4"}},{"id":4617446,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-09-14T22:25:45.000Z","date":"2026-09-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":2905,"price":40.94,"value":118930.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares."}],"balance_after":106905,"source":{"system":"sec-edgar","filing":"0001209181-26-000005","document":"wk-form4_1789424742.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000120918126000005/wk-form4_1789424742.xml","form_type":"4"}},{"id":4615523,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32848,"kind":"person","name":"Fitzgerald Meghan","position":1,"cik":"0001349297","reported_name":"Fitzgerald Meghan","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-11T01:00:26.000Z","date":"2026-09-08","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Reflects an award of stock options to purchase Common Shares that is fully vested."}],"balance_after":18578,"derivative":{"exercise_price":8.8,"expiration_date":"2033-04-19","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001140361-26-036246","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036126036246/form4.xml","form_type":"4"}},{"id":4615522,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32848,"kind":"person","name":"Fitzgerald Meghan","position":1,"cik":"0001349297","reported_name":"Fitzgerald Meghan","relationship":{"director":true}}],"security":"Common Shares","published_at":"2026-09-11T01:00:26.000Z","date":"2026-09-08","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":39.9,"value":798000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.90 to $40.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026."}],"balance_after":42963,"source":{"system":"sec-edgar","filing":"0001140361-26-036246","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036126036246/form4.xml","form_type":"4"}},{"id":4615521,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32848,"kind":"person","name":"Fitzgerald Meghan","position":1,"cik":"0001349297","reported_name":"Fitzgerald Meghan","relationship":{"director":true}}],"security":"Common Shares","published_at":"2026-09-11T01:00:26.000Z","date":"2026-09-08","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":8.8,"value":176000.0,"ownership":{"direct":true},"balance_after":62963,"source":{"system":"sec-edgar","filing":"0001140361-26-036246","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036126036246/form4.xml","form_type":"4"}},{"id":671257,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-02T01:00:30.000Z","date":"2026-08-28","kind":"exercise","planned":true,"acquired":false,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Reflects an award of stock options to purchase Common Shares that is fully vested."}],"balance_after":3844834,"derivative":{"exercise_price":3.85,"expiration_date":"2032-04-19","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001140361-26-035375","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036126035375/form4.xml","form_type":"4"}},{"id":671256,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2026-09-02T01:00:30.000Z","date":"2026-08-28","kind":"sale","planned":true,"acquired":false,"shares":33818,"price":36.44,"value":1232327.92,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.17 to $36.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025."}],"balance_after":1599154,"source":{"system":"sec-edgar","filing":"0001140361-26-035375","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036126035375/form4.xml","form_type":"4"}},{"id":671255,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2026-09-02T01:00:30.000Z","date":"2026-08-28","kind":"sale","planned":true,"acquired":false,"shares":166182,"price":35.63,"value":5921064.66,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.17 to $36.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025."}],"balance_after":1632972,"source":{"system":"sec-edgar","filing":"0001140361-26-035375","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036126035375/form4.xml","form_type":"4"}},{"id":671254,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2026-09-02T01:00:30.000Z","date":"2026-08-28","kind":"exercise","planned":true,"acquired":true,"shares":200000,"price":3.85,"value":770000.0,"ownership":{"direct":true},"balance_after":1799154,"source":{"system":"sec-edgar","filing":"0001140361-26-035375","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036126035375/form4.xml","form_type":"4"}},{"id":677585,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":20422,"kind":"person","name":"Pulik Richard","position":1,"cik":"0001885841","reported_name":"Pulik Richard","relationship":{"officer":true,"officer_title":"CFO"}}],"security":"Common Shares","published_at":"2026-08-25T01:00:21.000Z","date":"2026-08-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":5749,"price":36.84,"value":211793.16,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes Common Shares purchased under the Issuer's Employee Stock Purchase Plan."}],"balance_after":271810,"source":{"system":"sec-edgar","filing":"0001140361-26-034239","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885841/000114036126034239/form4.xml","form_type":"4"}},{"id":677465,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2026-08-25T01:00:09.000Z","date":"2026-08-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":13909,"price":36.84,"value":512407.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."}],"balance_after":1599154,"source":{"system":"sec-edgar","filing":"0001140361-26-034238","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036126034238/form4.xml","form_type":"4"}},{"id":678835,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":20848,"kind":"person","name":"Sukhatme Mayukh","position":1,"cik":"0001750050","reported_name":"Sukhatme Mayukh","relationship":{"director":true,"officer":true,"officer_title":"President & CIO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-22T01:00:32.000Z","date":"2026-08-21","kind":"exercise","planned":false,"acquired":false,"shares":144756,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Award of stock options to purchase Common Shares that is fully vested."}],"balance_after":13224363,"derivative":{"exercise_price":3.85,"expiration_date":"2032-04-19","underlying":"Common Shares","underlying_shares":144756},"source":{"system":"sec-edgar","filing":"0001140361-26-034066","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1750050/000114036126034066/form4.xml","form_type":"4"}},{"id":678834,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":20848,"kind":"person","name":"Sukhatme Mayukh","position":1,"cik":"0001750050","reported_name":"Sukhatme Mayukh","relationship":{"director":true,"officer":true,"officer_title":"President & CIO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-22T01:00:32.000Z","date":"2026-08-20","kind":"exercise","planned":false,"acquired":false,"shares":17519,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Award of stock options to purchase Common Shares that is fully vested."}],"balance_after":13369119,"derivative":{"exercise_price":3.85,"expiration_date":"2032-04-19","underlying":"Common Shares","underlying_shares":17519},"source":{"system":"sec-edgar","filing":"0001140361-26-034066","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1750050/000114036126034066/form4.xml","form_type":"4"}},{"id":678833,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":20848,"kind":"person","name":"Sukhatme Mayukh","position":1,"cik":"0001750050","reported_name":"Sukhatme Mayukh","relationship":{"director":true,"officer":true,"officer_title":"President & CIO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-22T01:00:32.000Z","date":"2026-08-19","kind":"exercise","planned":false,"acquired":false,"shares":172899,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Award of stock options to purchase Common Shares that is fully vested."}],"balance_after":13386638,"derivative":{"exercise_price":3.85,"expiration_date":"2032-04-19","underlying":"Common Shares","underlying_shares":172899},"source":{"system":"sec-edgar","filing":"0001140361-26-034066","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1750050/000114036126034066/form4.xml","form_type":"4"}},{"id":678832,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":20848,"kind":"person","name":"Sukhatme Mayukh","position":1,"cik":"0001750050","reported_name":"Sukhatme Mayukh","relationship":{"director":true,"officer":true,"officer_title":"President & CIO"}}],"security":"Common Shares","published_at":"2026-08-22T01:00:32.000Z","date":"2026-08-21","kind":"sale","planned":false,"acquired":false,"shares":144756,"price":36.48,"value":5280698.88,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.25 to $37.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range."}],"balance_after":18630739,"source":{"system":"sec-edgar","filing":"0001140361-26-034066","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1750050/000114036126034066/form4.xml","form_type":"4"}},{"id":678831,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":20848,"kind":"person","name":"Sukhatme Mayukh","position":1,"cik":"0001750050","reported_name":"Sukhatme Mayukh","relationship":{"director":true,"officer":true,"officer_title":"President & CIO"}}],"security":"Common Shares","published_at":"2026-08-22T01:00:32.000Z","date":"2026-08-21","kind":"exercise","planned":false,"acquired":true,"shares":144756,"price":3.85,"value":557310.6,"ownership":{"direct":true},"balance_after":18775495,"source":{"system":"sec-edgar","filing":"0001140361-26-034066","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1750050/000114036126034066/form4.xml","form_type":"4"}},{"id":678830,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":20848,"kind":"person","name":"Sukhatme Mayukh","position":1,"cik":"0001750050","reported_name":"Sukhatme Mayukh","relationship":{"director":true,"officer":true,"officer_title":"President & CIO"}}],"security":"Common Shares","published_at":"2026-08-22T01:00:32.000Z","date":"2026-08-20","kind":"sale","planned":false,"acquired":false,"shares":17519,"price":37.3,"value":653458.7,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.20 to $37.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range."}],"balance_after":18630739,"source":{"system":"sec-edgar","filing":"0001140361-26-034066","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750050/000114036126034066/form4.xml","form_type":"4"}},{"id":678829,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":20848,"kind":"person","name":"Sukhatme Mayukh","position":1,"cik":"0001750050","reported_name":"Sukhatme Mayukh","relationship":{"director":true,"officer":true,"officer_title":"President & CIO"}}],"security":"Common Shares","published_at":"2026-08-22T01:00:32.000Z","date":"2026-08-20","kind":"exercise","planned":false,"acquired":true,"shares":17519,"price":3.85,"value":67448.15,"ownership":{"direct":true},"balance_after":18648258,"source":{"system":"sec-edgar","filing":"0001140361-26-034066","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750050/000114036126034066/form4.xml","form_type":"4"}},{"id":678828,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":20848,"kind":"person","name":"Sukhatme Mayukh","position":1,"cik":"0001750050","reported_name":"Sukhatme Mayukh","relationship":{"director":true,"officer":true,"officer_title":"President & CIO"}}],"security":"Common Shares","published_at":"2026-08-22T01:00:32.000Z","date":"2026-08-19","kind":"sale","planned":false,"acquired":false,"shares":172899,"price":37.17,"value":6426655.83,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.80 to $37.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range."}],"balance_after":18630739,"source":{"system":"sec-edgar","filing":"0001140361-26-034066","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750050/000114036126034066/form4.xml","form_type":"4"}},{"id":678827,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":20848,"kind":"person","name":"Sukhatme Mayukh","position":1,"cik":"0001750050","reported_name":"Sukhatme Mayukh","relationship":{"director":true,"officer":true,"officer_title":"President & CIO"}}],"security":"Common Shares","published_at":"2026-08-22T01:00:32.000Z","date":"2026-08-19","kind":"exercise","planned":false,"acquired":true,"shares":172899,"price":3.85,"value":665661.15,"ownership":{"direct":true},"balance_after":18803638,"source":{"system":"sec-edgar","filing":"0001140361-26-034066","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750050/000114036126034066/form4.xml","form_type":"4"}},{"id":683621,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":20848,"kind":"person","name":"Sukhatme Mayukh","position":1,"cik":"0001750050","reported_name":"Sukhatme Mayukh","relationship":{"director":true,"officer":true,"officer_title":"President & CIO"}}],"security":"Common Shares","published_at":"2026-08-19T01:00:15.000Z","date":"2026-08-18","kind":"exercise","planned":false,"acquired":false,"shares":136942,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Award of stock options to purchase Common Shares that is fully vested."}],"balance_after":13559537,"derivative":{"exercise_price":3.85,"expiration_date":"2032-04-19","underlying":"Common Shares","underlying_shares":136942},"source":{"system":"sec-edgar","filing":"0001140361-26-033637","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1750050/000114036126033637/form4.xml","form_type":"4"}},{"id":683620,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":20848,"kind":"person","name":"Sukhatme Mayukh","position":1,"cik":"0001750050","reported_name":"Sukhatme Mayukh","relationship":{"director":true,"officer":true,"officer_title":"President & CIO"}}],"security":"Common Shares","published_at":"2026-08-19T01:00:15.000Z","date":"2026-08-17","kind":"exercise","planned":false,"acquired":false,"shares":284707,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Award of stock options to purchase Common Shares that is fully vested."}],"balance_after":13696479,"derivative":{"exercise_price":3.85,"expiration_date":"2032-04-19","underlying":"Common Shares","underlying_shares":284707},"source":{"system":"sec-edgar","filing":"0001140361-26-033637","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1750050/000114036126033637/form4.xml","form_type":"4"}},{"id":683619,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":20848,"kind":"person","name":"Sukhatme Mayukh","position":1,"cik":"0001750050","reported_name":"Sukhatme Mayukh","relationship":{"director":true,"officer":true,"officer_title":"President & CIO"}}],"security":"Common Shares","published_at":"2026-08-19T01:00:15.000Z","date":"2026-08-14","kind":"exercise","planned":false,"acquired":false,"shares":243177,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Award of stock options to purchase Common Shares that is fully vested."}],"balance_after":13981186,"derivative":{"exercise_price":3.85,"expiration_date":"2032-04-19","underlying":"Common Shares","underlying_shares":243177},"source":{"system":"sec-edgar","filing":"0001140361-26-033637","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1750050/000114036126033637/form4.xml","form_type":"4"}},{"id":683618,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":20848,"kind":"person","name":"Sukhatme Mayukh","position":1,"cik":"0001750050","reported_name":"Sukhatme Mayukh","relationship":{"director":true,"officer":true,"officer_title":"President & CIO"}}],"security":"Common Shares","published_at":"2026-08-19T01:00:15.000Z","date":"2026-08-18","kind":"sale","planned":false,"acquired":false,"shares":31801,"price":37.18,"value":1182361.18,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.10 to $37.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range."}],"balance_after":18630739,"source":{"system":"sec-edgar","filing":"0001140361-26-033637","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1750050/000114036126033637/form4.xml","form_type":"4"}},{"id":683617,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":20848,"kind":"person","name":"Sukhatme Mayukh","position":1,"cik":"0001750050","reported_name":"Sukhatme Mayukh","relationship":{"director":true,"officer":true,"officer_title":"President & CIO"}}],"security":"Common Shares","published_at":"2026-08-19T01:00:15.000Z","date":"2026-08-18","kind":"exercise","planned":false,"acquired":true,"shares":31801,"price":3.85,"value":122433.85,"ownership":{"direct":true},"balance_after":18662540,"source":{"system":"sec-edgar","filing":"0001140361-26-033637","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1750050/000114036126033637/form4.xml","form_type":"4"}},{"id":683616,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":20848,"kind":"person","name":"Sukhatme Mayukh","position":1,"cik":"0001750050","reported_name":"Sukhatme Mayukh","relationship":{"director":true,"officer":true,"officer_title":"President & CIO"}}],"security":"Common Shares","published_at":"2026-08-19T01:00:15.000Z","date":"2026-08-18","kind":"sale","planned":false,"acquired":false,"shares":105141,"price":36.59,"value":3847109.19,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.10 to $37.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range."}],"balance_after":18630739,"source":{"system":"sec-edgar","filing":"0001140361-26-033637","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1750050/000114036126033637/form4.xml","form_type":"4"}},{"id":683615,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":20848,"kind":"person","name":"Sukhatme Mayukh","position":1,"cik":"0001750050","reported_name":"Sukhatme Mayukh","relationship":{"director":true,"officer":true,"officer_title":"President & CIO"}}],"security":"Common Shares","published_at":"2026-08-19T01:00:15.000Z","date":"2026-08-18","kind":"exercise","planned":false,"acquired":true,"shares":105141,"price":3.85,"value":404792.85,"ownership":{"direct":true},"balance_after":18735880,"source":{"system":"sec-edgar","filing":"0001140361-26-033637","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1750050/000114036126033637/form4.xml","form_type":"4"}},{"id":683614,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":20848,"kind":"person","name":"Sukhatme Mayukh","position":1,"cik":"0001750050","reported_name":"Sukhatme Mayukh","relationship":{"director":true,"officer":true,"officer_title":"President & CIO"}}],"security":"Common Shares","published_at":"2026-08-19T01:00:15.000Z","date":"2026-08-17","kind":"sale","planned":false,"acquired":false,"shares":284707,"price":36.25,"value":10320628.75,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.10 to $36.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range."}],"balance_after":18630739,"source":{"system":"sec-edgar","filing":"0001140361-26-033637","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750050/000114036126033637/form4.xml","form_type":"4"}},{"id":683613,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":20848,"kind":"person","name":"Sukhatme Mayukh","position":1,"cik":"0001750050","reported_name":"Sukhatme Mayukh","relationship":{"director":true,"officer":true,"officer_title":"President & CIO"}}],"security":"Common Shares","published_at":"2026-08-19T01:00:15.000Z","date":"2026-08-17","kind":"exercise","planned":false,"acquired":true,"shares":284707,"price":3.85,"value":1096121.95,"ownership":{"direct":true},"balance_after":18915446,"source":{"system":"sec-edgar","filing":"0001140361-26-033637","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750050/000114036126033637/form4.xml","form_type":"4"}},{"id":683612,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":20848,"kind":"person","name":"Sukhatme Mayukh","position":1,"cik":"0001750050","reported_name":"Sukhatme Mayukh","relationship":{"director":true,"officer":true,"officer_title":"President & CIO"}}],"security":"Common Shares","published_at":"2026-08-19T01:00:15.000Z","date":"2026-08-14","kind":"sale","planned":false,"acquired":false,"shares":243177,"price":36.23,"value":8810302.71,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.10 to $36.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range."}],"balance_after":18630739,"source":{"system":"sec-edgar","filing":"0001140361-26-033637","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750050/000114036126033637/form4.xml","form_type":"4"}},{"id":683611,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":20848,"kind":"person","name":"Sukhatme Mayukh","position":1,"cik":"0001750050","reported_name":"Sukhatme Mayukh","relationship":{"director":true,"officer":true,"officer_title":"President & CIO"}}],"security":"Common Shares","published_at":"2026-08-19T01:00:15.000Z","date":"2026-08-14","kind":"exercise","planned":false,"acquired":true,"shares":243177,"price":3.85,"value":936231.45,"ownership":{"direct":true},"balance_after":18873916,"source":{"system":"sec-edgar","filing":"0001140361-26-033637","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750050/000114036126033637/form4.xml","form_type":"4"}},{"id":701487,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-30T01:00:10.000Z","date":"2026-07-27","kind":"exercise","planned":true,"acquired":false,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Reflects an award of stock options to purchase Common Shares that is fully vested."}],"balance_after":4044834,"derivative":{"exercise_price":3.85,"expiration_date":"2032-04-19","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001140361-26-030107","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036126030107/form4.xml","form_type":"4"}},{"id":701486,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2026-07-30T01:00:10.000Z","date":"2026-07-27","kind":"sale","planned":true,"acquired":false,"shares":200000,"price":34.95,"value":6990000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.62 to $35.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range."}],"balance_after":1613063,"source":{"system":"sec-edgar","filing":"0001140361-26-030107","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036126030107/form4.xml","form_type":"4"}},{"id":701485,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"officer":true,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2026-07-30T01:00:10.000Z","date":"2026-07-27","kind":"exercise","planned":true,"acquired":true,"shares":200000,"price":3.85,"value":770000.0,"ownership":{"direct":true},"balance_after":1813063,"source":{"system":"sec-edgar","filing":"0001140361-26-030107","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000114036126030107/form4.xml","form_type":"4"}},{"id":705181,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true}}],"security":"Common Shares","published_at":"2026-07-22T01:00:18.000Z","date":"2026-07-17","kind":"grant","planned":false,"acquired":true,"shares":405,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date."}],"balance_after":109810,"source":{"system":"sec-edgar","filing":"0001140361-26-029193","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036126029193/form4.xml","form_type":"4"}},{"id":705208,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true}}],"security":"Common Shares","published_at":"2026-07-22T01:00:17.000Z","date":"2026-07-17","kind":"grant","planned":false,"acquired":true,"shares":543,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date."}],"balance_after":17017,"source":{"system":"sec-edgar","filing":"0001140361-26-029192","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000114036126029192/form4.xml","form_type":"4"}},{"id":705182,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29297,"kind":"person","name":"Oren Ilan","position":1,"cik":"0001643073","reported_name":"Oren Ilan","relationship":{"director":true}}],"security":"Common Shares","published_at":"2026-07-22T01:00:16.000Z","date":"2026-07-17","kind":"grant","planned":false,"acquired":true,"shares":775,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date."}],"balance_after":121004,"source":{"system":"sec-edgar","filing":"0001140361-26-029191","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1643073/000114036126029191/form4.xml","form_type":"4"}},{"id":717908,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2026-07-02T23:06:02.000Z","date":"2026-06-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":76171,"price":35.39,"value":2695691.69,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."}],"balance_after":16659945,"source":{"system":"sec-edgar","filing":"0001635088-26-000079","document":"wk-form4_1783033560.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000163508826000079/wk-form4_1783033560.xml","form_type":"4"}},{"id":717906,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32848,"kind":"person","name":"Fitzgerald Meghan","position":1,"cik":"0001349297","reported_name":"Fitzgerald Meghan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T23:03:57.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Award of stock options to purchase Common Shares that is fully vested."}],"balance_after":38578,"derivative":{"exercise_price":8.8,"expiration_date":"2033-04-19","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001349297-26-000004","document":"wk-form4_1783033435.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000134929726000004/wk-form4_1783033435.xml","form_type":"4"}},{"id":717905,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32848,"kind":"person","name":"Fitzgerald Meghan","position":1,"cik":"0001349297","reported_name":"Fitzgerald Meghan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-07-02T23:03:57.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":34.9,"value":349000.0,"ownership":{"direct":true},"balance_after":42963,"source":{"system":"sec-edgar","filing":"0001349297-26-000004","document":"wk-form4_1783033435.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000134929726000004/wk-form4_1783033435.xml","form_type":"4"}},{"id":717904,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32848,"kind":"person","name":"Fitzgerald Meghan","position":1,"cik":"0001349297","reported_name":"Fitzgerald Meghan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-07-02T23:03:57.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":8.8,"value":88000.0,"ownership":{"direct":true},"balance_after":52963,"source":{"system":"sec-edgar","filing":"0001349297-26-000004","document":"wk-form4_1783033435.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000134929726000004/wk-form4_1783033435.xml","form_type":"4"}},{"id":717907,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32849,"kind":"person","name":"Torti Frank","position":1,"cik":"0001647805","reported_name":"Torti Frank","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and Vant Chair"}}],"security":"Common Shares","published_at":"2026-07-02T23:01:12.000Z","date":"2026-06-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":40310,"price":35.39,"value":1426570.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."}],"balance_after":13536202,"source":{"system":"sec-edgar","filing":"0001635088-26-000077","document":"wk-form4_1783033269.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000163508826000077/wk-form4_1783033269.xml","form_type":"4"}},{"id":718100,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":20848,"kind":"person","name":"Sukhatme Mayukh","position":1,"cik":"0001750050","reported_name":"Sukhatme Mayukh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CIO"}}],"security":"Common Shares","published_at":"2026-07-02T23:00:03.000Z","date":"2026-06-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":46878,"price":35.39,"value":1659012.42,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."}],"balance_after":18630739,"source":{"system":"sec-edgar","filing":"0001635088-26-000075","document":"wk-form4_1783033200.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750050/000163508826000075/wk-form4_1783033200.xml","form_type":"4"}},{"id":721336,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-01T22:34:22.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":false,"shares":17750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Reflects an award of stock options to purchase Common Shares that is fully vested."}],"balance_after":169166,"derivative":{"exercise_price":4.46,"expiration_date":"2032-07-19","underlying":"Common Stock","underlying_shares":17750},"source":{"system":"sec-edgar","filing":"0001807359-26-000010","document":"wk-form4_1782945259.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000180735926000010/wk-form4_1782945259.xml","form_type":"4"}},{"id":721335,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-07-01T22:34:22.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":2748,"price":34.71,"value":95383.08,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.65 to $34.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range."}],"balance_after":16474,"source":{"system":"sec-edgar","filing":"0001807359-26-000010","document":"wk-form4_1782945259.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000180735926000010/wk-form4_1782945259.xml","form_type":"4"}},{"id":721334,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-07-01T22:34:22.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":15002,"price":34.32,"value":514868.64,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.65 to $34.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range."}],"balance_after":19222,"source":{"system":"sec-edgar","filing":"0001807359-26-000010","document":"wk-form4_1782945259.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000180735926000010/wk-form4_1782945259.xml","form_type":"4"}},{"id":721333,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-07-01T22:34:22.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":true,"shares":17750,"price":4.46,"value":79165.0,"ownership":{"direct":true},"balance_after":34224,"source":{"system":"sec-edgar","filing":"0001807359-26-000010","document":"wk-form4_1782945259.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000180735926000010/wk-form4_1782945259.xml","form_type":"4"}},{"id":722772,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":34463,"kind":"person","name":"MANCHESTER KEITH S","position":1,"cik":"0001244828","reported_name":"MANCHESTER KEITH S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-07-01T00:38:34.000Z","date":"2026-06-30","kind":"sale","planned":false,"acquired":false,"shares":200000,"price":35.45,"value":7090000.0,"ownership":{"direct":true},"balance_after":1748403,"source":{"system":"sec-edgar","filing":"0001193125-26-291172","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000119312526291172/ownership.xml","form_type":"4"}},{"id":722771,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":34463,"kind":"person","name":"MANCHESTER KEITH S","position":1,"cik":"0001244828","reported_name":"MANCHESTER KEITH S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-07-01T00:38:34.000Z","date":"2026-06-30","kind":"sale","planned":false,"acquired":false,"shares":12380,"price":35.28,"value":436766.4,"ownership":{"direct":false,"nature":"Held by QVT Financial Investment Cayman Ltd."},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. (\"QVT FIC\") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose."}],"balance_after":13689166,"source":{"system":"sec-edgar","filing":"0001193125-26-291172","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000119312526291172/ownership.xml","form_type":"4"}},{"id":722770,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":34463,"kind":"person","name":"MANCHESTER KEITH S","position":1,"cik":"0001244828","reported_name":"MANCHESTER KEITH S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-07-01T00:38:34.000Z","date":"2026-06-29","kind":"sale","planned":false,"acquired":false,"shares":600000,"price":34.59,"value":20754000.0,"ownership":{"direct":false,"nature":"Held by QVT Financial Investment Cayman Ltd."},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. (\"QVT FIC\") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose."}],"balance_after":13701546,"source":{"system":"sec-edgar","filing":"0001193125-26-291172","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000119312526291172/ownership.xml","form_type":"4"}},{"id":722769,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":34463,"kind":"person","name":"MANCHESTER KEITH S","position":1,"cik":"0001244828","reported_name":"MANCHESTER KEITH S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-07-01T00:38:34.000Z","date":"2026-06-29","kind":"sale","planned":false,"acquired":false,"shares":200000,"price":34.44,"value":6888000.0,"ownership":{"direct":false,"nature":"Held by QVT Financial Investment Cayman Ltd."},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. (\"QVT FIC\") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose."}],"balance_after":14301546,"source":{"system":"sec-edgar","filing":"0001193125-26-291172","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000119312526291172/ownership.xml","form_type":"4"}},{"id":722768,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":34463,"kind":"person","name":"MANCHESTER KEITH S","position":1,"cik":"0001244828","reported_name":"MANCHESTER KEITH S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-07-01T00:38:34.000Z","date":"2026-06-26","kind":"sale","planned":false,"acquired":false,"shares":325000,"price":34.07,"value":11072750.0,"ownership":{"direct":false,"nature":"Held by QVT Financial Investment Cayman Ltd."},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. (\"QVT FIC\") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose."}],"balance_after":14501546,"source":{"system":"sec-edgar","filing":"0001193125-26-291172","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000119312526291172/ownership.xml","form_type":"4"}},{"id":722767,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":34463,"kind":"person","name":"MANCHESTER KEITH S","position":1,"cik":"0001244828","reported_name":"MANCHESTER KEITH S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-07-01T00:38:34.000Z","date":"2026-06-26","kind":"sale","planned":false,"acquired":false,"shares":300783,"price":33.92,"value":10202559.36,"ownership":{"direct":false,"nature":"Held by QVT Financial Investment Cayman Ltd."},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. (\"QVT FIC\") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose."}],"balance_after":14826546,"source":{"system":"sec-edgar","filing":"0001193125-26-291172","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000119312526291172/ownership.xml","form_type":"4"}},{"id":722766,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":22745,"kind":"person","name":"Gold Daniel Allen","position":1,"cik":"0001832142","reported_name":"Gold Daniel Allen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-07-01T00:30:07.000Z","date":"2026-06-30","kind":"sale","planned":false,"acquired":false,"shares":12380,"price":35.28,"value":436766.4,"ownership":{"direct":false,"nature":"Held by QVT Financial Investment Cayman Ltd."},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reporting person is one of three directors of QVT Financial Investment Cayman Ltd. (\"QVT FIC\"), sharing voting and investment control over the Common Shares held directly by QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose."}],"balance_after":13689166,"source":{"system":"sec-edgar","filing":"0001193125-26-291163","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000119312526291163/ownership.xml","form_type":"4"}},{"id":722765,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":22745,"kind":"person","name":"Gold Daniel Allen","position":1,"cik":"0001832142","reported_name":"Gold Daniel Allen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-07-01T00:30:07.000Z","date":"2026-06-29","kind":"sale","planned":false,"acquired":false,"shares":600000,"price":34.59,"value":20754000.0,"ownership":{"direct":false,"nature":"Held by QVT Financial Investment Cayman Ltd."},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reporting person is one of three directors of QVT Financial Investment Cayman Ltd. (\"QVT FIC\"), sharing voting and investment control over the Common Shares held directly by QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose."}],"balance_after":13701546,"source":{"system":"sec-edgar","filing":"0001193125-26-291163","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000119312526291163/ownership.xml","form_type":"4"}},{"id":722764,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":22745,"kind":"person","name":"Gold Daniel Allen","position":1,"cik":"0001832142","reported_name":"Gold Daniel Allen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-07-01T00:30:07.000Z","date":"2026-06-29","kind":"sale","planned":false,"acquired":false,"shares":200000,"price":34.44,"value":6888000.0,"ownership":{"direct":false,"nature":"Held by QVT Financial Investment Cayman Ltd."},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reporting person is one of three directors of QVT Financial Investment Cayman Ltd. (\"QVT FIC\"), sharing voting and investment control over the Common Shares held directly by QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose."}],"balance_after":14301546,"source":{"system":"sec-edgar","filing":"0001193125-26-291163","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000119312526291163/ownership.xml","form_type":"4"}},{"id":722763,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":22745,"kind":"person","name":"Gold Daniel Allen","position":1,"cik":"0001832142","reported_name":"Gold Daniel Allen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-07-01T00:30:07.000Z","date":"2026-06-26","kind":"sale","planned":false,"acquired":false,"shares":325000,"price":34.07,"value":11072750.0,"ownership":{"direct":false,"nature":"Held by QVT Financial Investment Cayman Ltd."},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reporting person is one of three directors of QVT Financial Investment Cayman Ltd. (\"QVT FIC\"), sharing voting and investment control over the Common Shares held directly by QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose."}],"balance_after":14501546,"source":{"system":"sec-edgar","filing":"0001193125-26-291163","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000119312526291163/ownership.xml","form_type":"4"}},{"id":722762,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":22745,"kind":"person","name":"Gold Daniel Allen","position":1,"cik":"0001832142","reported_name":"Gold Daniel Allen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-07-01T00:30:07.000Z","date":"2026-06-26","kind":"sale","planned":false,"acquired":false,"shares":300783,"price":33.92,"value":10202559.36,"ownership":{"direct":false,"nature":"Held by QVT Financial Investment Cayman Ltd."},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reporting person is one of three directors of QVT Financial Investment Cayman Ltd. (\"QVT FIC\"), sharing voting and investment control over the Common Shares held directly by QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose."}],"balance_after":14826546,"source":{"system":"sec-edgar","filing":"0001193125-26-291163","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000119312526291163/ownership.xml","form_type":"4"}},{"id":722761,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":22839,"kind":"organization","name":"QVT Financial LP","position":1,"cik":"0001290162","reported_name":"QVT Financial LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Director by Deputization"}}],"security":"Common Shares","published_at":"2026-06-30T23:59:10.000Z","date":"2026-06-30","kind":"sale","planned":false,"acquired":false,"shares":12380,"price":35.28,"value":436766.4,"ownership":{"direct":false,"nature":"Held by QVT Financial Investment Cayman Ltd."},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Aggregately, following the transactions described above, QVT Financial LP (\"QVT\"), a Delaware limited partnership, may be deemed to be the beneficial owner of 23,723,074 Common Shares, consisting of the Common Shares owned by QVT P&E Roiv Hldgs Ltd. (\"QVT P&E\"), QVT Deferred Compensation Holdings Ltd (\"QVT DCH\") and QVT FIC. QVT Financial GP LLC (\"QVT Financial GP\"), a Delaware limited liability company, is the general partner of QVT and may be deemed to beneficially own the same number of Common Shares reported by QVT."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"QVT provides certain investment advisory services for, and thereby may be deemed to beneficially own the Common Shares held by, QVT P&E, QVT DCH and QVT FIC. QVT disclaims beneficial ownership of such Common Shares, except to the extent of any pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose."}],"balance_after":13689166,"source":{"system":"sec-edgar","filing":"0001193125-26-291139","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000119312526291139/ownership.xml","form_type":"4"}},{"id":722760,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":22839,"kind":"organization","name":"QVT Financial LP","position":1,"cik":"0001290162","reported_name":"QVT Financial LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Director by Deputization"}}],"security":"Common Shares","published_at":"2026-06-30T23:59:10.000Z","date":"2026-06-29","kind":"sale","planned":false,"acquired":false,"shares":600000,"price":34.59,"value":20754000.0,"ownership":{"direct":false,"nature":"Held by QVT Financial Investment Cayman Ltd."},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Aggregately, following the transactions described above, QVT Financial LP (\"QVT\"), a Delaware limited partnership, may be deemed to be the beneficial owner of 23,723,074 Common Shares, consisting of the Common Shares owned by QVT P&E Roiv Hldgs Ltd. (\"QVT P&E\"), QVT Deferred Compensation Holdings Ltd (\"QVT DCH\") and QVT FIC. QVT Financial GP LLC (\"QVT Financial GP\"), a Delaware limited liability company, is the general partner of QVT and may be deemed to beneficially own the same number of Common Shares reported by QVT."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"QVT provides certain investment advisory services for, and thereby may be deemed to beneficially own the Common Shares held by, QVT P&E, QVT DCH and QVT FIC. QVT disclaims beneficial ownership of such Common Shares, except to the extent of any pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose."}],"balance_after":13701546,"source":{"system":"sec-edgar","filing":"0001193125-26-291139","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000119312526291139/ownership.xml","form_type":"4"}},{"id":722759,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":22839,"kind":"organization","name":"QVT Financial LP","position":1,"cik":"0001290162","reported_name":"QVT Financial LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Director by Deputization"}}],"security":"Common Shares","published_at":"2026-06-30T23:59:10.000Z","date":"2026-06-29","kind":"sale","planned":false,"acquired":false,"shares":200000,"price":34.44,"value":6888000.0,"ownership":{"direct":false,"nature":"Held by QVT Financial Investment Cayman Ltd."},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Aggregately, following the transactions described above, QVT Financial LP (\"QVT\"), a Delaware limited partnership, may be deemed to be the beneficial owner of 23,723,074 Common Shares, consisting of the Common Shares owned by QVT P&E Roiv Hldgs Ltd. (\"QVT P&E\"), QVT Deferred Compensation Holdings Ltd (\"QVT DCH\") and QVT FIC. QVT Financial GP LLC (\"QVT Financial GP\"), a Delaware limited liability company, is the general partner of QVT and may be deemed to beneficially own the same number of Common Shares reported by QVT."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"QVT provides certain investment advisory services for, and thereby may be deemed to beneficially own the Common Shares held by, QVT P&E, QVT DCH and QVT FIC. QVT disclaims beneficial ownership of such Common Shares, except to the extent of any pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose."}],"balance_after":14301546,"source":{"system":"sec-edgar","filing":"0001193125-26-291139","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000119312526291139/ownership.xml","form_type":"4"}},{"id":722758,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":22839,"kind":"organization","name":"QVT Financial LP","position":1,"cik":"0001290162","reported_name":"QVT Financial LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Director by Deputization"}}],"security":"Common Shares","published_at":"2026-06-30T23:59:10.000Z","date":"2026-06-26","kind":"sale","planned":false,"acquired":false,"shares":325000,"price":34.07,"value":11072750.0,"ownership":{"direct":false,"nature":"Held by QVT Financial Investment Cayman Ltd."},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Aggregately, following the transactions described above, QVT Financial LP (\"QVT\"), a Delaware limited partnership, may be deemed to be the beneficial owner of 23,723,074 Common Shares, consisting of the Common Shares owned by QVT P&E Roiv Hldgs Ltd. (\"QVT P&E\"), QVT Deferred Compensation Holdings Ltd (\"QVT DCH\") and QVT FIC. QVT Financial GP LLC (\"QVT Financial GP\"), a Delaware limited liability company, is the general partner of QVT and may be deemed to beneficially own the same number of Common Shares reported by QVT."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"QVT provides certain investment advisory services for, and thereby may be deemed to beneficially own the Common Shares held by, QVT P&E, QVT DCH and QVT FIC. QVT disclaims beneficial ownership of such Common Shares, except to the extent of any pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose."}],"balance_after":14501546,"source":{"system":"sec-edgar","filing":"0001193125-26-291139","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000119312526291139/ownership.xml","form_type":"4"}},{"id":722757,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":22839,"kind":"organization","name":"QVT Financial LP","position":1,"cik":"0001290162","reported_name":"QVT Financial LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Director by Deputization"}}],"security":"Common Shares","published_at":"2026-06-30T23:59:10.000Z","date":"2026-06-26","kind":"sale","planned":false,"acquired":false,"shares":300783,"price":33.92,"value":10202559.36,"ownership":{"direct":false,"nature":"Held by QVT Financial Investment Cayman Ltd."},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Aggregately, following the transactions described above, QVT Financial LP (\"QVT\"), a Delaware limited partnership, may be deemed to be the beneficial owner of 23,723,074 Common Shares, consisting of the Common Shares owned by QVT P&E Roiv Hldgs Ltd. (\"QVT P&E\"), QVT Deferred Compensation Holdings Ltd (\"QVT DCH\") and QVT FIC. QVT Financial GP LLC (\"QVT Financial GP\"), a Delaware limited liability company, is the general partner of QVT and may be deemed to beneficially own the same number of Common Shares reported by QVT."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"QVT provides certain investment advisory services for, and thereby may be deemed to beneficially own the Common Shares held by, QVT P&E, QVT DCH and QVT FIC. QVT disclaims beneficial ownership of such Common Shares, except to the extent of any pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose."}],"balance_after":14826546,"source":{"system":"sec-edgar","filing":"0001193125-26-291139","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000119312526291139/ownership.xml","form_type":"4"}},{"id":724090,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":20848,"kind":"person","name":"Sukhatme Mayukh","position":1,"cik":"0001750050","reported_name":"Sukhatme Mayukh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CIO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-29T22:23:06.000Z","date":"2026-06-26","kind":"exercise","planned":false,"acquired":false,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Award of stock options to purchase Common Shares that is fully vested."}],"balance_after":14224363,"derivative":{"exercise_price":3.85,"expiration_date":"2032-04-19","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001635088-26-000073","document":"wk-form4_1782771783.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1750050/000163508826000073/wk-form4_1782771783.xml","form_type":"4"}},{"id":724089,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":20848,"kind":"person","name":"Sukhatme Mayukh","position":1,"cik":"0001750050","reported_name":"Sukhatme Mayukh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CIO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-29T22:23:06.000Z","date":"2026-06-25","kind":"exercise","planned":false,"acquired":false,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Award of stock options to purchase Common Shares that is fully vested."}],"balance_after":14724363,"derivative":{"exercise_price":3.85,"expiration_date":"2032-04-19","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001635088-26-000073","document":"wk-form4_1782771783.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1750050/000163508826000073/wk-form4_1782771783.xml","form_type":"4"}},{"id":724088,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":20848,"kind":"person","name":"Sukhatme Mayukh","position":1,"cik":"0001750050","reported_name":"Sukhatme Mayukh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CIO"}}],"security":"Common Shares","published_at":"2026-06-29T22:23:06.000Z","date":"2026-06-26","kind":"sale","planned":false,"acquired":false,"shares":500000,"price":34.08,"value":17040000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.75 to $34.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range."}],"balance_after":18677617,"source":{"system":"sec-edgar","filing":"0001635088-26-000073","document":"wk-form4_1782771783.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750050/000163508826000073/wk-form4_1782771783.xml","form_type":"4"}},{"id":724087,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":20848,"kind":"person","name":"Sukhatme Mayukh","position":1,"cik":"0001750050","reported_name":"Sukhatme Mayukh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CIO"}}],"security":"Common Shares","published_at":"2026-06-29T22:23:06.000Z","date":"2026-06-26","kind":"exercise","planned":false,"acquired":true,"shares":500000,"price":3.85,"value":1925000.0,"ownership":{"direct":true},"balance_after":19177617,"source":{"system":"sec-edgar","filing":"0001635088-26-000073","document":"wk-form4_1782771783.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750050/000163508826000073/wk-form4_1782771783.xml","form_type":"4"}},{"id":724086,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":20848,"kind":"person","name":"Sukhatme Mayukh","position":1,"cik":"0001750050","reported_name":"Sukhatme Mayukh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CIO"}}],"security":"Common Shares","published_at":"2026-06-29T22:23:06.000Z","date":"2026-06-25","kind":"sale","planned":false,"acquired":false,"shares":500000,"price":34.13,"value":17065000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.87 to $34.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range."}],"balance_after":18677617,"source":{"system":"sec-edgar","filing":"0001635088-26-000073","document":"wk-form4_1782771783.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750050/000163508826000073/wk-form4_1782771783.xml","form_type":"4"}},{"id":724085,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":20848,"kind":"person","name":"Sukhatme Mayukh","position":1,"cik":"0001750050","reported_name":"Sukhatme Mayukh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CIO"}}],"security":"Common Shares","published_at":"2026-06-29T22:23:06.000Z","date":"2026-06-25","kind":"exercise","planned":false,"acquired":true,"shares":500000,"price":3.85,"value":1925000.0,"ownership":{"direct":true},"balance_after":19177617,"source":{"system":"sec-edgar","filing":"0001635088-26-000073","document":"wk-form4_1782771783.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750050/000163508826000073/wk-form4_1782771783.xml","form_type":"4"}},{"id":725558,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & Immunovant CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-26T22:13:50.000Z","date":"2026-06-24","kind":"exercise","planned":true,"acquired":false,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Reflects an award of stock options to purchase Common Shares that is fully vested."}],"balance_after":4244834,"derivative":{"exercise_price":3.85,"expiration_date":"2032-04-19","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001635088-26-000071","document":"wk-form4_1782512028.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000163508826000071/wk-form4_1782512028.xml","form_type":"4"}},{"id":725557,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":17975,"kind":"person","name":"Venker Eric","position":1,"cik":"0001801917","reported_name":"Venker Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & Immunovant CEO"}}],"security":"Common Shares","published_at":"2026-06-26T22:13:50.000Z","date":"2026-06-24","kind":"sale","planned":true,"acquired":false,"shares":46234,"price":33.51,"value":1549301.34,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.23 to $33.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range."}],"balance_after":1613063,"source":{"system":"sec-edgar","filing":"0001635088-26-000071","document":"wk-form4_1782512028.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801917/000163508826000071/wk-form4_1782512028.xml","form_type":"4"}}],"next_cursor":"2026-06-26T22:13:50.000000Z,725557"}